Latest Market Entry News

EVE Health Group’s subsidiary Nextract has inked a pivotal two-year agreement with TeleDocs Clinic, enabling nationwide online prescribing of its upcoming erectile dysfunction and dysmenorrhea products ahead of regulatory approval.

EMVision Medical Devices has secured a $5 million non-dilutive government grant to accelerate global commercialisation of its innovative First Responder portable brain scanner, aimed at revolutionising pre-hospital stroke and brain injury care.

NH3 Clean Energy reports strong Pre-FEED results for its WAH2 clean ammonia project, highlighting robust economics and strategic partnerships while facing key risks around gas supply and funding.

Cleo Diagnostics unveils a pioneering blood test for early ovarian cancer detection, boasting superior accuracy to existing methods and targeting a significant U.S. market opportunity.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.

Botanix Pharmaceuticals has secured a US$30 million debt facility from Kreos Capital, bolstering its financial position to commercialize Sofdra™ and pursue platform expansion opportunities.

Optiscan Imaging Ltd has launched InSpecta™, a cutting-edge microscopic imaging device tailored for veterinary medicine, marking its strategic entry into a booming $12 billion US market. The device promises to revolutionize diagnostics and treatment for companion animals with real-time, non-invasive imaging.

Imricor Medical Systems has secured CE Mark approval for its NorthStar Mapping System ahead of schedule, marking a pivotal shift to software-centric MRI-guided cardiac interventions across Europe and the Middle East.

Jade Gas Holdings has launched Mongolia’s inaugural horizontal Coal Bed Methane production wells at the Red Lake field, signaling a pivotal step in the country’s energy transition. The company also appoints Chris Whiteman as interim CEO amid strategic leadership changes.

PainChek has advanced its US regulatory approval process with a positive FDA meeting, setting the stage for a potential market debut of its pain assessment app in late 2025.

Adveritas Limited reports a record 61% increase in annualised recurring revenue, driven by strong gains in sports betting and new product launches, while preparing for a strategic expansion into North America.

InhaleRx has secured swift Human Research Ethics Committee approval for its redesigned IRX-211 Phase 2 trial, expanding participant numbers and potentially bypassing Phase 3 to speed market entry.